Clinical
Xultophy: new diabetes drug
In Clinical
Let’s get clinical. Follow the links below to find out more about the latest clinical insight in community pharmacy.Bookmark
Record learning outcomes
The EC has granted marketing authorisation for Xultophy, which combines once-daily basal insulin degludec and a GLP-1 receptor agonist (liraglutide) in one pen for adults with type 2 diabetes.
Xultophy is added to oral hypoglycaemics when the latter (alone or with basal insulin) do not provide adequate control